Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Dicerna Pharma (NASDAQ:DRNA) on Friday, setting a price target of $45, which is approximately 66.79% above the present share price of $26.98.
Foroohar expects Dicerna Pharma to post earnings per share (EPS) of -$0.29 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Dicerna Pharma, with an average price target of $38.
The analysts price targets range from a high of $45 to a low of $35.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $48.88 million and a net profit of -$22.9 million. The company's market cap is $2.02 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 2.8% and a 47.73% success rate.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.